{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:28Z","timestamp":1777599088354,"version":"3.51.4"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1097\/gco.0000000000000082","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T13:21:30Z","timestamp":1403270490000},"page":"237-242","source":"Crossref","is-referenced-by-count":30,"title":["Selective progesterone receptor modulators"],"prefix":"10.1097","volume":"26","author":[{"given":"Lucy H.R.","family":"Whitaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair R.W.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary O.D.","family":"Critchley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-4-20210129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0889-8545(05)70302-8","article-title":"Epidemiology of endometriosis.","volume":"24","author":"Eskenazi","year":"1997","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators.","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.","volume":"22","author":"Williams","year":"2007","journal-title":"Hum Reprod"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial.","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/humrep\/den494","article-title":"Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene.","volume":"24","author":"Wilkens","year":"2009","journal-title":"PTEN Hum Reprod"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R10-4-20210129","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate.","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","article-title":"Effects of progesterone on uterine leiomyoma growth and apoptosis.","volume":"65","author":"Maruo","year":"2000","journal-title":"Steroids"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejogrb.2012.07.023","article-title":"Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.","volume":"165","author":"Talaulikar","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery.","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids.","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.mce.2012.02.021","article-title":"The immninent dawn of SPRMs in obstetrics and gynecology.","volume":"358","author":"Chabbert-Buffet","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R16-4-20210129","first-page":"CD007687","article-title":"Mifepristone for uterine fibroids.","volume":"8","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.fertnstert.2013.08.039","article-title":"Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis.","volume":"100","author":"Shen","year":"2013","journal-title":"Fertil Steril"},{"key":"R18-4-20210129","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy.","volume":"93","author":"Wilkens","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-4-20210129","doi-asserted-by":"crossref","first-page":"436174","DOI":"10.1155\/2012\/436174","article-title":"Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo.","volume":"2012","author":"Horak","year":"2012","journal-title":"Int J Endocrinol"},{"key":"R21-4-20210129","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.AOG.0000239440.02284.45","article-title":"Progesterone receptor modulator for emergency contraception: a randomized controlled trial.","volume":"108","author":"Creinin","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2013.05.010","article-title":"Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens.","volume":"88","author":"Brache","year":"2013","journal-title":"Contraception"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.contraception.2011.10.003","article-title":"Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.","volume":"85","author":"Brache","year":"2012","journal-title":"Contraception"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jcem.87.1.8140","article-title":"Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5mg per day for 120 days.","volume":"87","author":"Brown","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-4-20210129","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":"A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).","volume":"22","author":"Lakha","year":"2007","journal-title":"Hum Reprod"},{"key":"R27-4-20210129","first-page":"CD002122","article-title":"Progestagens and antiprogestagens for pain associated with endometriosis.","volume":"3","author":"Brown","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejps.2010.01.012","article-title":"A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies.","volume":"39","author":"Mei","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1093\/oxfordjournals.humrep.a135900","article-title":"Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.","volume":"10","author":"Stoeckemann","year":"1995","journal-title":"Hum Reprod"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejogrb.2013.03.022","article-title":"The effects of ulipristal on BaxBcl-2, cytochrome C, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis.","volume":"169","author":"Huniadi","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R32-4-20210129","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00404-012-2379-2","article-title":"Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model.","volume":"286","author":"Li","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"R33-4-20210129","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushings syndrome: a consensus statement.","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-4-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP13127.RA","article-title":"Pasireotide and mifepristone: new options in the medical management of Cushings disease.","volume":"20","author":"Cohan","year":"2014","journal-title":"Endocr Pract"},{"key":"R35-4-20210129","doi-asserted-by":"crossref","first-page":"e60984","DOI":"10.1371\/journal.pone.0060984","article-title":"Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.","volume":"8","author":"Debono","year":"2013","journal-title":"PLoS One"},{"key":"R36-4-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.","volume":"283","author":"Schairer","year":"2000","journal-title":"J Am Med Assoc"},{"key":"R37-4-20210129","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"key":"R38-4-20210129","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.1130471","article-title":"Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.","volume":"314","author":"Poole","year":"2006","journal-title":"Science"},{"key":"R43-4-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","article-title":"Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer.","volume":"35","author":"Robertson","year":"1999","journal-title":"Eur J Cancer"},{"key":"R44-4-20210129","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/humrep\/des221","article-title":"Ulipristal acetate does not impact human normal breast tissue.","volume":"27","author":"Communal","year":"2012","journal-title":"Hum Reprod"},{"key":"R45-4-20210129","first-page":"1053","article-title":"High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis.","volume":"29","author":"Moe","year":"2009","journal-title":"Anticancer Res"},{"key":"R46-4-20210129","first-page":"1237","article-title":"Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study.","volume":"22","author":"Jurado","year":"2009","journal-title":"Oncol Rep"},{"key":"R47-4-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I","article-title":"Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.","volume":"42","author":"El Etreby","year":"2000","journal-title":"Prostate"},{"key":"R48-4-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-11-207","article-title":"Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and nonreproductive origin regardless of progesterone receptor expression.","volume":"11","author":"Tieszen","year":"2011","journal-title":"BMC Cancer"},{"key":"R49-4-20210129","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1158\/1078-0432.CCR-07-0164","article-title":"Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.","volume":"13","author":"Goyeneche","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R50-4-20210129","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10637-011-9655-z","article-title":"Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.","volume":"30","author":"Goyeneche","year":"2012","journal-title":"Invest New Drugs"},{"key":"R51-4-20210129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsbmb.2012.04.005","article-title":"Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.","volume":"132","author":"Hernandez-Hernandez","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R52-4-20210129","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/02688697.2011.629696","article-title":"Study of effectiveness of mifepristone for glioma cell line growth suppression.","volume":"26","author":"Ramaswamy","year":"2012","journal-title":"Br J Neurosurg"},{"key":"R53-4-20210129","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2407-12-200","article-title":"Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.","volume":"12","author":"Gamarra-Luques","year":"2012","journal-title":"BMC Cancer"},{"key":"R54-4-20210129","first-page":"142","article-title":"Mifepristone sensitizing cisplatin for cervical adenocarcinoma HeLa cell sensitivity to chemotherapy and its mechanism.","volume":"34","author":"Li","year":"2013","journal-title":"Eur J Gynaecol Oncol"}],"container-title":["Current Opinion in Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GCO.0000000000000082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:42:02Z","timestamp":1620952922000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001703-201408000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0000000000000082","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}